Treatment Control Ethanol t-statistic P< Value
Vehicle 6.54 ± 0.59 11.21 ± 1.12 2.601 0.05
PPAR-α 11.27 ± 1.75 31.35 ± 3.06 12.60 0.0001
PPAR-δ 5.28 ± 0.53 7.35 ± 0.41 1.406 N.S.
PPAR-γ 9.47 ± 1.07 14.92 ± 1.10 4.017 0.001
Liver tissue homogenates were analyzed for lipid content using the Nile Red fluorometric assay. Values reflect mean ± S.E.M. fluorescence light units corrected for protein content in the sample. 2-way ANOVA tests demonstrated significant effects of ethanol (F=113.42; df=84; P<00001), PPAR agonist treatments (F=50.19, df=84; P<0.0001), and interactions between ethanol exposure and PPAR agonist treatments (F=30.56, df=84; P<0.0001). Bonferroni posttests demonstrated significant between group differences as indicated by the t-statistic and P-value in the Table.
Table 1: Effects of PPAR Agonist Treatments on Liver Lipid Content in Chronic Alcohol-Induced Liver Disease.